- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02307292
Prospective, Post Market Surveillance Q3-registry (POLARIS) (Q3-Registry)
January 9, 2015 updated by: Hans Krankenberg, QualiMed Innovative Medizinprodukte GmbH
Prospective, Non-randomized Post Market Surveillance Registry to Document the Clinical Performance in Routine Clinical Practice of the POLARIS Peripheral Vascular Self Expanding Stent System.
This is a prospective, non-randomized post market surveillance registry designed to document the clinical Performance in Routine clinical practice of the POLARIS Peripheral Vascular Self Expanding Stent System
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
250
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bad Bevensen, Germany, 29549
- Recruiting
- HGZ Bad Bevensen, Department of Angiology
-
Contact:
- Hans Krankenberg, MD, PhD
- Phone Number: +495821821157
- Email: h.krankenberg@hgz-bb.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with single significant (>50%) superficial femoral artery disease
Description
Inclusion Criteria:
- Age >18 years
- Single target de novo superficial femoral artery lesion (angiographic evidence of >50% Stenosis or occlusion) by visual estimate
- Rutherford category II-IV
- At least one patent outflow artery to the ankle.
- Patient signed the informed consent
Exclusion Criteria:
- Patient with acute or subacute Thrombus
- Patients with hyperkoagulopathy
- Patients with Stenosis or occlusion where lesion crossing with guide wire is not possible
- Pregnancy or positive pregnancy test
- Previous enrolment in this Trial or other industrial Trials
- Patient´s inability to fully cooperate with the registry protocol Patient with cancer Treatment (life expectancy less than 2 years) Patients with renal failure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Freedom from target lesion revascularization
Time Frame: at 12 months
|
Clinically driven
|
at 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Binary restenosis/ reocclusion
Time Frame: at 12 months
|
Defined as peak systolic velocity tatio (PSVR) > 2.4
|
at 12 months
|
|
Target limb amputation at the index leg (major and minor separately)
Time Frame: at 12 months
|
at 12 months
|
|
|
All-cause death
Time Frame: at 12 months
|
at 12 months
|
|
|
Change in resting ankle brachial index (ABI)
Time Frame: From baseline to 12 and 24 months
|
From baseline to 12 and 24 months
|
|
|
Change in Rutherford Classification
Time Frame: From baseline to 12 and 24 months
|
From baseline to 12 and 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Hans Krankenberg, MD,PhD, Cardiovascular Center Bad Bevensen, Department of Angiology
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2014
Primary Completion (Anticipated)
April 1, 2017
Study Completion (Anticipated)
April 1, 2017
Study Registration Dates
First Submitted
November 18, 2014
First Submitted That Met QC Criteria
December 3, 2014
First Posted (Estimate)
December 4, 2014
Study Record Updates
Last Update Posted (Estimate)
January 12, 2015
Last Update Submitted That Met QC Criteria
January 9, 2015
Last Verified
January 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- QualiMed
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Artery Disease
-
Janssen Scientific Affairs, LLCHCA Research Institute, LLCCompletedCoronary Artery Disease (CAD) | Peripheral Artery Disease (PAD)United States
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedStructural Heart Disease | Obstructive Coronary Artery Disease | Obstructive Peripheral Artery DiseaseUnited States
-
Azienda Ospedaliero-Universitaria di ParmaActive, not recruiting
-
Michael Lichtenberg, MDCompletedPeripheral Artery Disease (PAD)Germany
-
XeltisRecruitingPeripheral Artery Occlusive DiseaseCosta Rica
-
Fangge DengRecruitingPeripheral Artery Disease (PAD)China
-
Fundacion para la Formacion e Investigacion Sanitarias...Not yet recruiting
-
Rontis Hellas SAPharmassist LtdActive, not recruitingPeripheral Artery Disease (PAD)Greece
-
Helsinki University Central HospitalCompletedPeripheral Artery Occlusive Disease | Peripheral Artery Stenosis | Peripheral Artery RestenosisFinland
Clinical Trials on POLARIS Peripheral Vascular Self Expanding Stent System
-
Abbott Medical DevicesBaim Institute for Clinical ResearchWithdrawnWith de Novo or Restenotic Lesions in the Common and/or External Iliac Arteries
-
Provascular GmbHBoston Scientific CorporationCompletedPeripheral Arterial Diseases | Superficial Femoral Artery StenosisGermany
-
Acotec Scientific Co., LtdRecruitingPeripheral Arterial Disease (PAD) | Peripheral Vascular Disease (PVD)China
-
Medtronic EndovascularCompletedPeripheral Arterial Disease | Lower Extremity Arterial DiseaseUnited States
-
Abbott Medical DevicesCompleted
-
FrontAce Scientific Co., LtdRecruitingPeripheral Arterial Disease | Stenosis | DissectionChina
-
Medtronic EndovascularCompleted
-
Terumo Medical CorporationActive, not recruitingIliac Artery StenosisUnited States
-
Sinomed Neurovita Technology Inc.Changhai HospitalCompletedIntracranial Arterial Diseases | Percutaneous Transluminal Angioplasty | Stent RestenosisChina
-
Medtronic EndovascularCompletedIliofemoral Venous ObstructionUnited States, France, Germany, United Kingdom, Ireland, Italy